NKTR — Nektar Therapeutics

Ownership history in BB BIOTECH AG  ·  4 quarters on record

This page tracks every 13F SEC filing in which BB BIOTECH AG reported a position in Nektar Therapeutics (NKTR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.71% (2019 Q1)
Avg. % of fund
1.32%
First filed
2018 Q2
Last filed
2019 Q1
Quarters held
4
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2019 Q1 ADDED 2,020,676 +639,701 +46.3% 1.71% $67.9M $504.00
2018 Q4 ADDED 1,380,975 +535,975 +63.4% 1.45% $45.4M $493.05
2018 Q3 ADDED 845,000 +320,000 +61.0% 1.36% $51.5M $914.40
2018 Q2 INITIATED 525,000 — — 0.74% $25.6M —
% of Fund (quarterly)    NKTR price (monthly, adj. close)

Other funds also holding NKTR

As of 2025 Q4 — sorted by position size

22NW, LP 3Y 7Y 5.89% Prosight Management, LP 3Y 7Y 4.85% Propel Bio Management, LLC 2.99% GREAT POINT PARTNERS LLC 3Y 7Y 2.89% Stonepine Capital Management, LLC 3Y 7Y 2.62% Deuterium Capital Management, LLC 3Y 2.29% Monashee Investment Management LLC 3Y 7Y 2.24% BVF INC/IL 3Y 7Y 2.22% Stonepine Capital Management, LLC 3Y 7Y 1.54% STEMPOINT CAPITAL LP 1.29%
← Back to BB BIOTECH AG Holdings